Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

First International Summit on Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Apr

Today In Oncology

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Melanoma Can AI Enable Diagnosis Prediction

AI Tool Shows Early Ability in Pinpointing Cells Driving Aggressive Cancers

DRUP Trial Investigates Use of Off-Label Drugs for Patients With Advanced Solid Tumors

Sequential or Concurrent Radiotherapy and Immunotherapy in Advanced Newly Diagnosed or Refractory NSCLC

Romiplostim for Chemotherapy-Induced Thrombocytopenia